Pharmacotherapy for Obesity: Ethical Considerations in Protecting Patient Welfare

Introduction

Obesity has become a global epidemic, presenting formidable challenges to public health systems and individuals alike. While lifestyle modifications such as diet and exercise remain cornerstones of obesity management, pharmacotherapy has emerged as a potential adjunctive treatment option for those struggling to attain weight loss goals. However, the integration of pharmacotherapy into obesity treatment raises significant ethical considerations that necessitate careful examination. (1)

This article explores the ethical dimensions surrounding the use of pharmacotherapy in obesity treatment, considering issues such as safety, efficacy, equity, autonomy, and societal impact.

Safety and Efficacy

The National Institute for Health and Care Excellence (NICE) currently recommends pharmacological interventions alongside lifestyle modifications for weight loss maintenance. However, the available pharmacotherapeutic options on the National Health Service (NHS) are somewhat limited, typically prescribed for individuals with a body mass index (BMI) exceeding specific thresholds. Notably, treatment discontinuation is advised if significant weight loss fails to materialize within three months. (2)

Pharmacotherapy for obesity

Orlistat

Among the pharmaceutical agents prescribed, Orlistat stands out as a prominent example. Operating through the irreversible inhibition of pancreatic lipases, Orlistat impedes dietary fat absorption, thereby facilitating weight loss. (3) Despite its efficacy, Orlistat is associated with gastrointestinal side effects, including oily stool and fecal urgency. These adverse effects necessitate adherence to a low-fat diet regimen, complicating patient management. (4)

Liraglutide (Saxenda®)

Another widely prescribed agent, Liraglutide, acts as a glucagon-like peptide-1 (GLP-1) receptor agonist, exerting dual effects on appetite suppression and glucose homeostasis regulation. While Liraglutide demonstrates significant weight reduction benefits, it is not without adverse effects, with gastrointestinal disturbances being the most commonly reported. (5)

The efficacy of Liraglutide has been underscored by several clinical trials, including the Safety and Clinical Adiposity-Liraglutide Evidence (SCALE) studies. These trials highlight not only the weight loss benefits but also improvements in metabolic parameters and cardiovascular risk factors associated with Liraglutide therapy. (6)

Naltrexone/Bupropion (Mysimba®)

Naltrexone/Bupropion combination therapy, although showing promise in aiding weight loss, is not currently recommended for long-term use by NICE. This caution is due to uncertainties surrounding its sustained effectiveness and the incidence of adverse effects. While offering appetite suppression through a synergistic mechanism, the tolerability of Naltrexone/Bupropion is marred by adverse events such as nausea and headaches. (7)

Ethical Considerations

The utilization of pharmacotherapy in obesity management raises several ethical considerations that warrant meticulous attention. Foremost among these is the principle of beneficence, ensuring that the benefits of treatment outweigh potential harms. Healthcare providers must carefully weigh the efficacy of pharmacological interventions against their safety profiles, striving to maximize patient outcomes while minimizing adverse effects.

Equity in access to obesity pharmacotherapy remains a critical ethical concern, particularly given disparities in healthcare access and affordability. The limited availability of these medications, coupled with financial constraints and insurance coverage limitations, may exacerbate existing health inequalities. Addressing these disparities demands a concerted effort to ensure equitable access to obesity management options for all individuals. (8)

Autonomy and Informed Consent

 Respect for patient autonomy is a fundamental ethical principle in healthcare decision-making. When considering pharmacotherapy for obesity, healthcare providers must ensure that patients are adequately informed about the potential risks, benefits, and alternatives. Informed consent requires a comprehensive understanding of treatment options, empowering patients to make autonomous choices aligned with their values and preferences. (9)

Discussion

Ethical considerations surrounding the use of pharmacotherapy for obesity are complex and multifaceted. Healthcare providers, policymakers, and ethicists must navigate these challenges to ensure that obesity management strategies uphold principles of beneficence, nonmaleficence, justice, and respect for autonomy. Multidisciplinary approaches that integrate medical, psychological, and social support are essential for addressing the diverse needs of individuals with obesity while minimizing potential ethical conflicts. (10)

Furthermore, ongoing research and surveillance are necessary to evaluate the long-term safety and effectiveness of pharmacotherapy for obesity, as well as its broader societal impacts. By fostering open dialogue and collaboration, stakeholders can work towards developing ethical guidelines and policies that promote evidence-based, patient-centered care for obesity management. (11)

Conclusion

The ethical considerations of using pharmacotherapy for obesity underscore the importance of balancing individual autonomy, safety, equity, and societal values. While pharmacotherapy may offer valuable support for some individuals in achieving weight loss goals, ethical decision-making requires careful deliberation of potential risks and benefits, as well as attention to broader social determinants of health. By upholding ethical principles and promoting inclusivity and compassion, healthcare providers can strive to ensure that obesity management approaches are both effective and ethically sound.

References

1.       Ruban, A., Stoenchev, K., Ashrafian, H., & Teare, J. (2019). Current treatments for obesity. Clinical medicine (London, England), 19(3), 205–212. https://doi.org/10.7861/clinmedicine.19-3-205.

2.       Hurt, R. T., Kulisek, C., Buchanan, L. A., & McClave, S. A. (2010). The obesity epidemic: challenges, health initiatives, and implications for gastroenterologists. Gastroenterology & hepatology, 6(12), 780–792.

3.       Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994;56:82–5.

4.       Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155–61.

5.       Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomized controlled trials. BMJ 2012;344:d7771.

6.       Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311–22.

7.       Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 2010;376:595–605.

8.       Manning, S., Pucci, A., & Finer, N. (2014). Pharmacotherapy for obesity: novel agents and paradigms. Therapeutic advances in chronic disease, 5(3), 135–148. https://doi.org/10.1177/2040622314522848.

9.       Varkey B. (2021). Principles of Clinical Ethics and Their Application to Practice. Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 30(1), 17–28. https://doi.org/10.1159/000509119.

10.     Mechanick, J. I., & Kushner, R. F. (2015). Past, present, and future of pharmacologic obesity treatment. Endocrine Practice, 21(12), 1403-1413.

11.     Gostin, L. O. (2017). Ethical principles for the conduct of human subject research: Population-based research and ethics. Journal of Law, Medicine & Ethics, 45(1_suppl), 25-29.

Read more such content on @ Hidoc Dr | Medical Learning App for Doctors